About us
Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.
We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.
Enara Bio is backed by prominent life science investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.
Leadership Team
President and Chief Executive Officer
Chief Operating Officer
Chief Medical Officer and Head of Translational Science
Chief Scientific Officer
Chief Business Officer and Chief Financial Officer
Board of Directors
Scientific Advisors & Founders
-
George Kassiotis, PhD
Co-founder of Enara Bio
Francis Crick Institute -
Mike Quigley, PhD
Sanofi CSO and Global Head of Research
Ex-Gilead and BMS R&D -
Drew Pardoll, MD PhD
Co-founder of Enara Bio
Johns Hopkins School of Medicine - Eliezer Van Allen, MD PhD Dana-Farber Cancer Institute / Harvard
-
Houman Ashrafian
Co-founder of Enara Bio
Sanofi EVP, Head of R&D -
Katherine Chiappinelli, PhD
Associate Professor
George Washington University Cancer Center
